Naronaprid Shows Promise in Treating Gastroparesis Symptoms

Gastroparesis is a chronic gastrointestinal disorder characterized by delayed stomach emptying, leading to symptoms such as early satiety, upper abdominal pain, nausea, vomiting, and a persistent feeling of fullness after meals. The condition significantly impacts patients' quality of life, and current therapeutic options are limited. Traditionally, prokinetic drugs like dopamine-2 receptor antagonists (such as metoclopramide and domperidone) and the serotonergic 5-HT4 receptor agonist prucalopride are used off-label, as none have official approval for gastroparesis treatment.

A new drug candidate, Naronaprid, is being investigated for its ability to improve gastrointestinal motility. This orally administered, locally acting prokinetic agent operates via a dual mechanism: it acts as both a 5-HT4 receptor agonist and a dopamine-D2 receptor antagonist. By targeting these two receptor types on the luminal surface of the gastrointestinal tract, Naronaprid aims to regulate gastric motility and mitigate symptoms such as nausea. The compound is minimally absorbed systemically, resulting in a localized effect within the digestive tract and potentially reducing systemic side effects.

Recent findings from the MOVE-IT clinical trial, a randomized, double-blind, placebo-controlled Phase IIb study, have generated attention in the medical community. The study evaluated Naronaprid's efficacy, safety, and tolerability in adults with moderate to severe idiopathic or diabetic gastroparesis, all of whom had objectively confirmed delayed gastric emptying.

In the twelve-week trial, 328 participants were assigned to receive either 10 mg, 20 mg, or 40 mg of Naronaprid, or a placebo, three times daily. The primary measure of effectiveness was the change from baseline in the weekly average Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) score at week twelve. This validated patient-reported tool assesses five core symptoms of gastroparesis: nausea, vomiting, early satiety, postprandial fullness, and upper abdominal pain.

The study's results indicated that patients receiving 20 mg or 40 mg of Naronaprid experienced statistically significant improvements in their symptom scores compared to those on placebo. According to the companies developing Naronaprid, its safety and tolerability profiles were favorable, with minimal systemic absorption reflected in the trial data. To date, Naronaprid has been evaluated in over 1,200 participants in clinical studies, with no major safety concerns observed.

Based on these promising results, plans are underway to advance Naronaprid into additional regulatory studies, which may eventually lead to its approval for gastroparesis treatment. However, further research and regulatory review are required before the drug can become widely available for clinical use.

Gastroparesis remains a challenging condition to manage, and the development of new, effective, and well-tolerated therapies such as Naronaprid could represent a significant advancement in the care of affected patients. Until then, patients and healthcare providers must rely on currently available treatments and ongoing research for improved outcomes.